Siham Sabri
Siham Sabri is an expert in Oncology at McGill University Health Centre (Canada). Siham Sabri has authored 93 publications, the most recent in 2025, and is an investigator in 1 clinical trial. SLR score: 275 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Neurology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 93
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Current insights on transglutaminase 2: Exploring its functions, mechanisms, and therapeutic potential in glioblastoma. PMID 40818831 — microscopy, electron, scanning transmission, brain, neoplasms, glioblastoma, therapeutics, apoptosis, transglutaminases | Crit Rev Oncol Hematol | 2025 | 0 |
| Response of non-small cell lung cancer harboring different epidermal growth factor receptor mutations to ablative radiotherapy. PMID 40673101 — radiotherapy, injections, cells, epidermal growth factor, lung, growth, cell survival, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, cell line, receptors, growth factor, small cell lung carcinoma, therapeutics, injections, subcutaneous, mutation, dose fractionation, radiation, heterografts, egfr mutation | Transl Lung Cancer Res | 2025 | 1 |
| Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells. PMID 39456455 — cells, microscopy, electron, scanning transmission, neoplasms, stem cells, oxidative stress, antioxidants, cell line, genes, p53, thioredoxins, glioblastoma, thioredoxin-disulfide reductase, auranofin, glutathione | Antioxidants (Basel) | 2024 | 1 |
| Pro-Oxidant Auranofin and Glutathione-Depleting Combination Unveils Synergistic Lethality in Glioblastoma Cells with Aberrant Epidermal Growth Factor Receptor Expression. PMID 39001381 — cells, epidermal growth factor, growth, glutamate-cysteine ligase, oxidants, oxidative stress, antioxidants, cell line, receptors, growth factor, thioredoxins, glioblastoma, down-regulation, auranofin, glutathione | Cancers (Basel) | 2024 | 3 |
| Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells. PMID 37958311 — apoptosis, antioxidants, cells, therapeutics, ovarian neoplasms, auranofin | Cancers (Basel) | 2023 | 10 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map